Ziopharm Oncology to Participate in September Investor Conferences
01 Septiembre 2021 - 3:05PM
Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq:
ZIOP), today announced that Kevin S. Boyle, Sr., Chief Executive
Officer of Ziopharm, is scheduled to participate in five upcoming
virtual investor conferences:
2021 Wells Fargo Virtual Healthcare
Conference |
Date: |
|
|
September 9, 2021 |
Presentation Time: |
|
|
10:00 am EDT |
|
|
|
|
Morgan Stanley 19th Annual Global
Healthcare Conference |
Date: |
|
|
September 10, 2021 |
No presentation – management available for
one-on-one meetings |
|
|
|
|
H.C. Wainwright
23rd Annual Global Investment
Conference |
Date: |
|
|
September 13, 2021 |
Time: |
|
|
7:00 am EDT (access to on demand webcast begins) |
|
|
|
|
Lake Street 5th Annual Best Ideas Growth
Conference |
Date: |
|
|
September 15, 2021 |
No presentation – management available for
one-on-one meetings |
|
|
|
|
2021 Cantor Virtual Global Healthcare
Conference |
Date: |
|
|
September 28, 2021 |
Presentation Time: |
|
|
3:20 pm EDT |
“As one of my initial priorities as CEO, I seek
to meet with our existing shareholders and hearing their
perspectives,” said Mr. Boyle. “I also welcome the opportunity to
introduce Ziopharm’s cutting-edge TCR science to potential new
investors.”
To access the webcast presentations, or the
subsequent archived recordings, please see the links above or visit
the “Investors” section of the Ziopharm website at
www.ziopharm.com.
About Ziopharm Oncology,
Inc.Ziopharm is developing non-viral and cytokine-driven
cell and gene therapies that weaponize the body’s immune system to
treat the millions of people globally diagnosed with cancer each
year. With its multiplatform approach, Ziopharm is at the forefront
of immuno-oncology. Ziopharm’s pipeline is built for commercially
scalable, cost-effective T-cell receptor (TCR) T-cell therapies
based on its non-viral Sleeping Beauty gene transfer platform, and
a Sleeping Beauty-enabled CD19-specific CAR-T program. The Company
has clinical and strategic collaborations with the National Cancer
Institute and The University of Texas MD Anderson Cancer Center.
For more information, please visit www.ziopharm.com.
Forward-Looking Statements
DisclaimerThis press release contains forward-looking
statements as defined in the Private Securities Litigation Reform
Act of 1995, as amended. Forward-looking statements are statements
that are not historical facts, and in some cases can be identified
by terms such as "may," "will," "could," "expects," "plans,"
"anticipates," and "believes." These statements include, but are
not limited to, statements regarding the Company's business and
strategic plans, the timing of activities relating to the Company’s
GMP facility, the execution of potential future partnerships or
transactions, and the timing of the Company's research and
development programs, including the anticipated dates for enrolling
patients in the Company’s TCR-T clinical trial. Although Ziopharm’s
management team believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned
that forward-looking information and statements are subject to
various risks and uncertainties, many of which are difficult to
predict and generally beyond the control of Ziopharm, that could
cause actual results and developments to differ materially from
those expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include,
among other things, changes in the Company’s operating plans that
may impact its cash expenditures, the uncertainties inherent in
research and development, future clinical data and analysis,
including whether any of Ziopharm’s product candidates will advance
further in the preclinical research or clinical trial process,
including receiving clearance from the U.S. Food and Drug
Administration or equivalent foreign regulatory agencies to
conduct clinical trials and whether and when, if at all, they will
receive final approval from the U.S. FDA or equivalent foreign
regulatory agencies and for which indication; the strength and
enforceability of Ziopharm’s intellectual property rights;
competition from other pharmaceutical and biotechnology companies
as well as risk factors discussed or identified in the public
filings with the Securities and Exchange Commission made by
Ziopharm, including those risks and uncertainties listed in
Ziopharm’s Quarterly Report in the most recent Form 10-Q and Form
10-K filed by Ziopharm with the Securities and Exchange Commission.
We are providing this information as of the date of this press
release, and Ziopharm does not undertake any obligation to update
or revise the information contained in this press release whether
as a result of new information, future events or any other
reason.
Investor Relations Contact:Adam D. Levy, Ph.D.,
MBAExecutive Vice President, Corporate Development and Investor
RelationsT: 508.552.9255E: alevy@ziopharm.com
ZIOPHARM Oncology (NASDAQ:ZIOP)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
ZIOPHARM Oncology (NASDAQ:ZIOP)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024